Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype and Allopurinol Dosing: 2015 update by Saito, Yoshiro et al.
Clinical Pharmacogenetics Implementation Consortium (CPIC) 
Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype 
and Allopurinol Dosing: 2015 update
Yoshiro Saito1, Lisa K Stamp2, Kelly E. Caudle3, Michael Hershfield4, Ellen M. McDonagh5, 
John T. Callaghan6,7,8, Wichittra Tassaneeyakul9, Taisei Mushiroda10, Naoyuki Kamatani11, 
Barry R. Goldspiel12, Elizabeth J. Phillips13,14, Teri E. Klein5, and Ming Ta Michael 
Lee15,16,17
1Division of Medicinal Safety Science, National Institute of Health Sciences, Kamiyoga, Setagaya, 
Tokyo, Japan 2Department of Medicine, University of Otago, Christchurch, New Zealand 
3Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 
4Departments of Medicine and Biochemistry, Duke University School of Medicine, Durham, NC, 
USA 5Department of Genetics, Stanford University Medical Center, Stanford, California, USA 
6ACOS for Research, Department of Veterans Affairs Medical Center, Indianapolis, Indiana, USA 
7Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA 
8Department of Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, 
Indiana, USA 9Department of Pharmacology, Research and Diagnostic Center for Emerging 
Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand 
10Laboratory for Pharmacogenetics, RIKEN, Center for Genomic Medicine, Yokohama, Japan 
11Institute of Data Analysis, StaGenCo.Ltd., Tokyo, Japan 12Pharmacy Department, National 
Institutes of Health Clinical Center, Bethesda, Maryland, USA 13Division of infectious diseases, 
Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia 
14Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN 
15Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative 
Medical Sciences, Yokohama, Japan 16National Center for Genome Medicine, Institute of 
Biomedical Sciences, Academia Sinica, Taipei, Taiwan 17School of Chinese Medicine, China 
Medical University, Taichung, Taiwan
Corresponding Author: Ming Ta Michael Lee, RIKEN Center for Genomic Medicine, 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, 
Japan 14101, Phone number: +81-45-503-9589, mikelee@src.riken.jp. 
Conflict of Interest: T.E.K. is a stockholder for Personalis Inc. L.K.S has been a consultant for Astra Zeneca. As of January 2015, 
E.M.M. is Lead Scientific Curator of Genomics England, Queen Mary University. M.S.H. is a co-inventor of Pegloticase 
(Krystexxa®) and receives royalties from Crealta Pharmaceuticals. The other authors declare no conflicts of interest.
Disclaimer: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical 
evidence and peer-reviewed literature available at the time they are written, and are intended only to assist clinicians in decision-
making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was 
submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. 
Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care 
or exclusive of other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for 
the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the 
clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's 
guidelines, or for any errors or omissions.
HHS Public Access
Author manuscript
Clin Pharmacol Ther. Author manuscript; available in PMC 2017 January 01.
Published in final edited form as:
Clin Pharmacol Ther. 2016 January ; 99(1): 36–37. doi:10.1002/cpt.161.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 
Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed recent 
literature and concluded that none of the evidence would change the therapeutic recommendations 
in the original guideline; therefore, the original publication remains clinically current. However, 
we have updated the supplemental material and included additional resources for applying CPIC 
guidelines into the electronic health record. Up-to-date information can be found at PharmGKB 
(http://www.pharmgkb.org).
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The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the 
Pharmacogenetics Research Network (http://www.pgrn.org) and the Pharmacogenomics 
Knowledge Base (PharmGKB, http://www.pharmgkb.org) provides peer-reviewed, 
evidence-based, freely accessible genotype-based drug guidelines to help clinicians 
understand how available genetic test results could be used to optimize drug therapy(1). 
CPIC guidelines undergo continuous peer review and information that would modify 
prescribing recommendations pertaining to gene specific alleles and nomenclature are 
updated periodically on the PharmGKB website. Furthermore, published CPIC guidelines 
are currently systematically reviewed for updates periodically.
The CPIC Guideline for HLA-B Genotype and Allopurinol Dosing was originally published 
in February 2013 (2). To update this guideline, we conducted a focused review of the 
literature published between 1966 to October 2014 on HLA genotype and allopurinol (see 
Supplemental material on-line). Our inclusion criteria for this guideline update also included 
other HLA variants besides HLA-B. The HLA-B*58:01 allele frequency tables 
(Supplemental Tables S1 and S2) have also been updated. The literature review yielded 26 
relevant primary studies showing association between HLA-B*58:01 and allopurinol SCAR 
(Supplemental Table S3). In addition, 12 studies showed associations for HLA-A*33:03 (7 
studies) or HLA-C*03:02 (5 studies) (Supplemental Table S3). However, the strength of the 
evidence for HLA-A*33:03 and HLA-C*03:02 did not warrant inclusion in this update 
(please see “other considerations” in the supplementary materials). We found no new 
evidence that would change our original recommendations for HLA-B*58:01 and allopurinol 
dosing; therefore, the original guideline publication and recommendation remains current 
(2). The 2012 American College of Rheumatology Guidelines for Management of Gout (3) 
recommends testing for the HLA-B*58:01 allele in selected subpopulations with elevated 
risk for allopurinol hypersensitivity syndrome (individuals of Korean decent with stage 3 or 
worse chronic kidney disease, and those of Han-Chinese or Thai decent) prior to initiation of 
the drug.
All new and updated CPIC guidelines will address dosing in pediatrics. Although none of 
the evidence linking HLA-B*58:01 to allopurinol hypersensitivity was conducted in 
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children, there is no reason to suspect that children positive for HLA-B*58:01 would be at 
less risk of allopurinol hypersensitivity reactions than adults positive for HLA-B*58:01.
CPIC guidelines are designed to help clinicians use genetic information to optimize drug 
therapy, and to do this effectively, pharmacogenetic information must be incorporated into 
electronic health records (EHRs) with clinical decision support (CDS) (4-6). To provide 
additional resources for applying CPIC guidelines into the EHR, CPIC created an 
informatics working group focused on supporting the adoption of CPIC guidelines within a 
clinical electronic environment. This guideline provides these clinical implementation 
resources as part of the supplementary material, which include workflow diagrams that 
illustrate the storage of a pharmacogenetic result in an EHR and the design of CDS alerts 
(Supplemental Figures S1 and S2). New tables that correspond to these workflow diagrams 
are provided that translate genotype test results into an interpreted phenotype (Supplemental 
Tables S4-S8). These tables provide summary genotype/phenotype terms, example text for 
documentation in the EHR and point-of-care alerts, and cross-references for drug and gene 
names to widely-used terminologies and standardized nomenclature systems.
We recognize that each organization and EHR vendor may have different requirements and 
preferences for implementing pharmacogenetics within a given electronic environment. The 
intent of these resources is to synthesize foundational knowledge that provides a common 
starting point for clinical implementation so that individual organizations do not have to 
create a similar knowledge base for each new gene/drug pair that is implemented. Future 
CPIC guidelines and guideline updates will provide similar resources to guide the 
implementation of gene-drug pairs into the EHR.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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